Shielding is a term used to describe the protection of individuals at high risk of severe COVID-19 illness by separating them from the general population.
The proposed roadmap includes components and recommended actions to eliminate these neglected infectious diseases from the Americas.
Addendum: 2020 mid-year COVID-19 revision,summary of the reprioritisation & additional requirements in response to COVID-19
In June and July 2020, a mid-year revision of the 2020 Burundi Regional Refugee Response Plan (RRRP) was undertaken as an inter-agency consultative process to discuss and doc...ument the reprioritization of activities and corresponding budgets for the rest of the year, taking into account the impacts of COVID-19 and other developments.
more
Updated version – September 2020
The COVID-19 pandemic is affecting everyone. Globally, millions of people have been infected with the virus, while hundreds of thousands have lost their lives. In Moldova, the pandemic is placing an ever-increasing pressure on the health care and social protectio...n systems, causing major disruptions to economic processes and limitations to social life, deepening inequalities and proving how vulnerable we are.
more
MEDBOX Issue Brief no. 6
This issue brief gives you an overview of the most important documents on humanitarian aid and the WASH sector in MEDBOX
Malnutrition in childhood and pregnancy has many adverse consequences for child survival and long-term well-being. It
also has far-reaching consequences for human capital, economic productivity, and national development overall. The
consequences of malnutrition should be a significant concern for ...policy makers in Burkina Faso, since around 672,000
children under 5 years (21 percent) suffer from chronic malnutrition (stunting or low height-for-age) and 10 percent
suffer from acute malnutrition (wasting or low weight-for-height) (Ministère de la Santé [MOH] et al. 2018).
more
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) causing coronavirus disease 2019 (COVID-19) has reached pandemic levels;
Patients with cardiovascular (CV) risk factors and established cardiovascular disease (CVD) represent a vulnerable population when suffering from COVID-19;
Patien...ts with cardiac injury in the context of COVID-19 have an increased risk of morbidity and mortality
more
What measures can we take to overcome the corona crisis, limit its consequences or use scarce resources efficiently? Every day we experience uncertainties and contradictions on these questions among scientists, health experts, politicians and in society. We must all strive for a broad consensus to o...vercome the global COVID-19 pandemic. With our publications IM FOKUS we want to stimulate discussion and promote opinion-forming: We write based on our experience of HIV work. We are not interested in COVID-19 to be equated with HIV, but to discuss which experiences from HIV work could be helpful in dealing with COVID-19. We do not intend to replace scientific papers, nor can we present the current state of knowledge comprehensively and conclusively.
more
16 Dec. 2020
This document provides guidance to Ministries of Health (MOHs), laboratory personnel and implementing partners in African Union Member States on the application of rapid antigen tests to COVID-19 testing. The guidance serves as reference for policymakers, laboratory leads, implementing... partners, and experts on use case scenarios and associated testing algorithms for COVID-19 antigen tests. It recommends the use of antigen tests to increase access to testing and enable timely results for persons with or without symptoms in specific settings. The document will be reviewed and updated as more evidence becomes available regarding the use of rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from global studies and evaluation efforts.
more
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
The authors state that researchers, governments and global agencies should proceed with particular care in the evaluation of candidate SARS-CoV-2 vaccines in LMICs, with effective communication to build trust and avoid generation of vaccine hesitancy. Vaccine efficacy is often highly variable betwee...n high-resource and low-resource settings
Archives of Disease in Childhood, vol.106 Issue 2
more
his Inter Action Review report for the COVID-19 outbreak in Mauritius documents and assesses the country’s capacity to respond to the outbreak and identifies the best practices, strengths, gaps and challenges of the national response. Areas requiring improvements or sustained actions have been ide...ntified across the 9 strategic pillars of World Health Organization (WHO)’s COVID-19 Strategic Preparedness and Response Plan and an additional pillar for the country’s response beyond health. On an overall, the review aims to enhance and sustain the national response with a particular focus on strengthening the health systems.
more
Reports of antimicrobial-resistant (AMR) microorganisms are increasing globally, threatening to render existing treatments ineffective against many infectious diseases. In Africa, AMR has already been documented to be a problem for human immunodeficiency virus (HIV) and the pathogens that cause mala...ria, tuberculosis (TB), typhoid, cholera, meningitis, gonorrhoea and dysentery. Recognizing the urgent need for action, the 2016 United Nations (UN) General Assembly approved a resolution to ensure sustained and effective global action to address AMR.
more
doi: https://doi.org/10.1101/2020.11.30.20236570
Pre-Print Article
My Child: 0 to 2 years is a free book from the HSE with advice to help you and your baby from birth to age 2. This edition has text in English with Arabic translation.
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more